May 19, 2025 08:00 ET | Source: Respira Therapeutics, Inc PALO ALTO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Respira…
Slowing of progression of disease observed via MRI at 24 months Improvements in outcomes and reduction in sorbitol maintained through…
Data confirmed TX45’s tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary…
Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month…
Antwerp, Belgium, May 6, 2025 – Agomab Therapeutics NV (“Agomab”) today announced late-breaking interim data from the ongoing STENOVA1 Phase…
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr…
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also…
Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease…
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and…
Met primary endpoint of safety and tolerability in CCM patients with no treatment-related discontinuations or Grade 3 adverse eventsIn comparison…
